CJC-1295 / Ipamorelin Therapy in San Diego, CA — Growth Hormone Stack
CJC-1295 and ipamorelin peptide therapy in San Diego — physician-supervised GHRH/GHRP stack for body composition, sleep, and recovery. By Dr. Joseph Dubroff, N.D.
Why the CJC/Ipa Stack Hits Harder Than Either Alone.
Growth hormone release is controlled by two different signaling pathways. Growth hormone-releasing hormone (GHRH) tells the pituitary to release GH on a slow, steady signal. Growth hormone-releasing peptides (GHRPs) — which mimic ghrelin — produce a sharper, more pulsatile release through a separate receptor system. The two pathways are synergistic: activate both simultaneously and you get a stronger, longer, more pronounced GH pulse than either pathway can produce alone.
That's the entire mechanistic reason CJC-1295 and ipamorelin are stacked together. CJC-1295 is a modified GHRH analog with extended half-life (longer-lasting GHRH signaling than sermorelin). Ipamorelin is a selective GHRP that triggers the ghrelin receptor pathway without the appetite stimulation or cortisol bump that older GHRPs caused. Combine them and you get amplified GH output through two complementary mechanisms — without injecting GH itself.
The CJC/Ipa stack is the more aggressive GH-axis option in Dr. Dubroff's practice. It's the protocol generally recommended for patients with specific body composition or recovery goals, or for patients who've tried sermorelin and want to step up to a stronger intervention.
How Each Half of the Stack Works.
Two peptides, two receptor systems, one synergistic GH response. Here's what each side of the protocol contributes.
CJC-1295
A modified version of growth hormone-releasing hormone with significantly extended half-life compared to native GHRH or sermorelin. Produces a sustained GHRH signal at the pituitary — essentially keeping the "release GH" message active for longer.
Comes in two main variants — with and without DAC (drug affinity complex). The DAC variant extends half-life dramatically and allows less frequent dosing. The non-DAC variant is shorter-acting and is generally what's used in the CJC/Ipa stack.
Ipamorelin
Triggers GH release through the ghrelin receptor pathway — a different mechanism from GHRH. Produces a sharp, pulsatile GH release that synergizes with the GHRH signal from CJC-1295.
The "selective" part matters: older GHRPs (GHRP-2, GHRP-6) also stimulated cortisol and appetite. Ipamorelin is more specific — it produces the GH release without the off-target effects, which is a substantial part of why it became the preferred GHRP in clinical use.
Which Belongs in Your Protocol?
Both options work on the same overall axis — increasing endogenous GH production. The differences are mechanism, intensity, and clinical fit. Sermorelin is the more conservative starting point. CJC/Ipa is the more aggressive, more targeted option.
The Goal Is Healthy Aging
You're 40+ and exploring GH-axis support for the first time, the primary goal is sleep quality and steady-state healthy aging, you prefer a more conservative starting protocol, or you have known sensitivity to peptides and want the gentler option. Sermorelin is also generally less expensive.
The Goal Is Body Composition
You have specific body composition or recovery goals, you've tried sermorelin and want to step up, you're an active athlete or training with intention and want a stronger GH stimulus, or you're optimizing for specific performance outcomes alongside training and nutrition. CJC/Ipa is the more aggressive intervention.
CJC-1295 / Ipamorelin FAQs
The Stronger GH-Axis Option.
Book a free consultation. Dr. Dubroff will run baseline IGF-1, talk through your goals, and tell you honestly whether CJC/Ipa, sermorelin, or another option best fits your situation.